18F-FDG and 68Ga-DOTATATE PET/CT in von Hippel-Lindau Disease-Associated Retinal Hemangioblastoma.

Clin Nucl Med

From the *Radiology and Imaging Sciences, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda; †PET-Department, Clinical Center, National Institutes of Health, Bethesda, MD; ‡Leeds Medical School, Leeds, UK; §Center for Research in Computer Vision, Electrical and Computer Science Department, University of Central Florida (UCF), Orlando, FL; ∥Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; ¶Endocrine and Thoracic Surgery, University Hospitals of Geneva, Geneva, Switzerland; and **Department of Radiology, Medical School, University of Crete, Crete, Greece.

Published: March 2017

Retinal hemangioblastomas are highly vascular benign tumors that can be encountered either sporadically or within the von Hippel-Lindau (VHL) syndrome. We report a case of a VHL patient with retinal hemangioblastoma who underwent PET/CT scans using F-FDG and Ga-DOTATATE. The tumor showed low-level F-FDG and increased Ga-DOTATATE activity, suggesting cell-surface overexpression of somatostatin receptors. The presented case indicates the clinical applications of somatostatin receptor imaging with Ga-DOTA-conjugated peptides in detection and follow-up of VHL manifestations, screening of asymptomatic gene carriers, and in diagnosis of sporadic retinal hemangioblastomas, which may have similar features on MRI with other retinal tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000001511DOI Listing

Publication Analysis

Top Keywords

von hippel-lindau
8
retinal hemangioblastoma
8
retinal hemangioblastomas
8
retinal
5
18f-fdg 68ga-dotatate
4
68ga-dotatate pet/ct
4
pet/ct von
4
hippel-lindau disease-associated
4
disease-associated retinal
4
hemangioblastoma retinal
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!